Cipla-NiPPharma In Respiratory Device Deal?
Cipla Ltd. is speculated to have struck a deal with Japan's NiPPharma Co., Ltd for a device apparently meant for the Indian firm's generic Advair dry powder inhaler (DPI) but some analysts suggest that limited visibility around the trials of the firm's salmeterol + fluticasone combination in the US stay a concern for now.
You may also be interested in...
The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.
The increasing urgency for GlaxoSmithKline PLC to build up its overall respiratory portfolio was underscored when Mylan NV confirmed it has submitted an abbreviated new drug application (ANDA) to the FDA for launch of the first generic alternative to GSK's top-selling Seretide Evohaler (salmeterol xinafoate + fluticasone propionate), known in the US as Advair Diskus.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.